Market Moves
CereGate raises Series C for a Parkinson's walking therapy
CereGate, a Munich company developing a therapy for freezing of gait in Parkinson's disease that runs on Boston Scientific deep brain stimulation implants, said on 14 October 2026 that an unnamed US medtech company had led its Series C. CereGate did not disclose the amount or its valuation. Its US trial began in April 2022, with main data collection due to finish in June 2027.